Eli Lilly and Company is in advanced discussions to acquire Kelonia Therapeutics for more than $2 billion, according to a report by The Wall Street Journal. The report, citing people familiar with the matter, indicates that a deal could be finalized as early as Monday and may include additional payments tied to the achievement of certain milestones.
Kelonia, based in Boston, operates as a clinical-stage biotechnology company focused on advancing a pipeline of genetic medicines across multiple disease areas, with a particular emphasis on CAR-T cell therapies. These therapies involve engineering a patient’s immune cells to recognize and eliminate cancer cells, positioning them as a key area of innovation in oncology.
A potential transaction would strengthen Lilly’s cancer portfolio, which already includes therapies such as Jaypirca and the breast cancer drug Verzenio, along with a range of emerging candidates. The Eli Lilly Kelonia acquisition would further reinforce the company’s presence in the rapidly evolving but highly competitive oncology segment, where demand for targeted and cell-based treatments continues to grow.
The Eli Lilly Kelonia acquisition also aligns with Lilly’s broader diversification strategy beyond its leadership in obesity treatments. The company has been expanding into therapeutic areas including inflammatory bowel disease, cancer, eye disorders and gene-editing technologies through a mix of acquisitions and partnerships. In a related development, Eli Lilly said in February that it would acquire Orna Therapeutics for up to $2.4 billion in cash, underscoring its continued focus on advancing next-generation genetic medicine platforms and strengthening its long-term pipeline.
